2.97
0.07 (2.41%)
| Previous Close | 2.90 |
| Open | 2.93 |
| Volume | 56,429 |
| Avg. Volume (3M) | 55,721 |
| Market Cap | 1,061,909,888 |
| Price / Earnings (Forward) | 204.08 |
| Price / Sales | 1.44 |
| Price / Book | 1.36 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | -26.26% |
| Operating Margin (TTM) | -9.91% |
| Diluted EPS (TTM) | -0.690 |
| Quarterly Revenue Growth (YOY) | -4.20% |
| Total Debt/Equity (MRQ) | 52.48% |
| Current Ratio (MRQ) | 2.03 |
| Operating Cash Flow (TTM) | 34.59 M |
| Levered Free Cash Flow (TTM) | -90.11 M |
| Return on Assets (TTM) | -2.42% |
| Return on Equity (TTM) | -20.51% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Drug Manufacturers - Specialty & Generic (US) | Mixed | Bullish |
| Drug Manufacturers - Specialty & Generic (Global) | Bullish | Bullish | |
| Stock | Evotec SE | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 1.67 |
|
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States. |
|
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Investment Style | Small Core |
| % Held by Institutions | 2.56% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Pitcairn Co | 30 Sep 2025 | 161,769 |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |